Combination therapy of photodynamic therapy and immune checkpoint inhibitor

By combining porphyrin dimer salt photosensitizers with immune checkpoint inhibitors, the immune system is activated, solving the treatment challenges of local recurrence and distant metastasis of esophageal cancer, and improving treatment efficacy and patient survival rates.

CN119015410APending Publication Date: 2024-11-26SHANGHAI GUANGSHENG BIOPHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310574518.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2023-05-19
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Among the existing treatments for esophageal cancer, the treatment effects on local recurrence and distant metastasis are not good, and immunotherapy has problems such as large individual differences and insufficient immunogenicity, and there is a lack of effective local control therapies.

Method used

The combined therapy of porphyrin dimer salt photosensitizer and immune checkpoint inhibitor is used to activate the immune system through photodynamic therapy, which, combined with immunotherapy, enhances the killing effect on esophageal cancer.

Benefits of technology

It significantly improved the effectiveness of esophageal cancer treatment, reduced the chances of tumor recurrence and metastasis, improved patients' quality of life, and laid a good foundation for subsequent palliative care.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004239595670000021
    Figure BDA0004239595670000021
  • Figure BDA0004239595670000101
    Figure BDA0004239595670000101
  • Figure BDA0004239595670000111
    Figure BDA0004239595670000111
Patent Text Reader

Abstract

The invention provides a combined treatment method of photodynamic therapy and immunotherapy, which comprises combined medication of a photosensitizer based on porphyrin dimer salt and an immune checkpoint inhibitor, and application of the combined treatment method for treating recurrent and / or metastatic cancers, especially esophageal cancers.
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present application relates to a combination therapy of photodynamic therapy and immune checkpoint inhibitors, and in particular, to a combination therapy for treating systemic or local recurrent and / or metastatic cancers, in particular esophageal cancer. Background Art

[0002] Esophageal cancer (EC) is the ninth most common cancer in the world and the sixth most common cancer in China. Radical treatments for EC include surgery, radical chemoradiotherapy, and drug therapy. However, most patients have already developed advanced disease at the time of diagnosis. Even after radical surgery or chemoradiotherapy, the recurrence rate of EC remains high, and the 5-year survival rate of patients with distant metastatic disease is only 4.8%.

[0003] The standard first-line treatment for EC is chemotherapy based on cisplatin + 5-Fu or paclitaxel. However, after progression of first-line treatment, systemic treatment options are limited and only effective in the short term. Radiotherapy is usually used for primary or locally recurrent tumors, but complications are high (such as radiation pneumonia, esophagitis, fistula, and bleeding), which makes the patient's prognosis worse and affects the quality of life. Local recurrence after radiotherapy is the main problem faced by patients with esophageal cancer. In recent years, immunotherapy has gradually become a second-line treatment option for patients. Clinical studies have shown that second-line immunotherapy is effective for esophageal squamous cell carcinoma (ESCC), with a remission rate of 16.7%. However, the main difficulties faced by immunotherapy alone are multifaceted, including large individual differences, insufficient immunogenicity, and weak intervention of local primary or recurrent lesions. Therefore, this field urgently needs to develop a new local control therapy with a high remission rate for local esophageal cancer and distal metastatic lesions, which may be an effective way to improve the remission rate in combination with other treatment options.

[0004] Photodynamic therapy (PDT) is a new method of treating diseases by using the photodynamic effect of photosensitizers. It is currently mainly used to treat and diagnose malignant tumors and certain precancerous lesions and benign lesions. After the photosensitizer is injected into the body, it will form a relatively high concentration of accumulation in the tumor tissue over a period of time. When irradiated with light of a specific wavelength, a strong photodynamic effect will occur, causing the diseased tissue to be fully destroyed. PDT has a certain selectivity for target tissues and good controllability of killing. Therefore, it can minimize the damage to normal tissues while ensuring the inactivation of tumors. It is a minimally invasive, low-toxic, non-thermogenic local treatment method, and therefore has broad application prospects.

[0005] The present invention provides a combined therapy of photodynamic therapy based on a photosensitizer of a porphyrin dimer salt and an immune checkpoint inhibitor for treating locally recurrent cancer, particularly esophageal cancer. Summary of the invention

[0006] In one aspect, the present application provides a photosensitizer suitable for treating cancer in an individual, wherein the photosensitizer comprises a porphyrin dimer salt, wherein the porphyrin dimer salt has a structure shown in formula (I), formula (II) or formula (III):

[0007]

[0008] in

[0009] R is independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy and C 1-6 acyl, which is optionally substituted by one or more substituents selected from halogen and hydroxy,

[0010] M is an alkali metal, an alkaline earth metal or NH 4 + ,

[0011] p is the reciprocal of the valence of M,

[0012] and solvates thereof, especially hydrates.

[0013] In certain embodiments, wherein R is independently selected from C optionally substituted with one or more hydroxyl groups 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 1-6 Acyl, M is an alkali metal or NH 4 + , and p is 1, and solvates thereof, especially hydrates.

[0014] In certain embodiments, wherein R is independently selected from -CH=CH 2 、-CH(OH)CH 3 and-COCH 3 , M is an alkali metal or NH 4 + , and p is 1, and solvates thereof, especially hydrates.

[0015] In certain embodiments, wherein R is independently selected from -CH=CH 2 and -CH(OH)CH 3 , M is an alkali metal or NH 4 +, and p is 1, and solvates thereof, especially hydrates.

[0016] In certain embodiments, wherein M is an alkali metal, such as Na or K.

[0017] In certain embodiments, the porphyrin dimer salt bound by an ether bond is selected from:

[0018] Bis[1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl]ether (DVDMS-1),

[0019] Bis[1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl]ether (DVDMS-2),

[0020] 1-[6,7-dipropanoic acid sodium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl 1-[6',7'-dipropanoic acid sodium-1',3',5',8'-tetramethyl-4-vinyl-2-porphine]ethyl ether (DVDMS-3),

[0021] Bis[1-[6,7-dipropanoic acid potassium-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl]ether,

[0022] Bis[1-[6,7-dipropanoic acid potassium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl]ether,

[0023] 1-[6,7-dipropionate potassium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl 1-[6',7'-dipropionate potassium-1',3',5',8'-tetramethyl-4-vinyl-2-porphine]ethyl ether,

[0024] Bis[1-[6,7-dipropionate ammonium-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl]ether,

[0025] Bis[1-[6,7-dipropionate ammonium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl]ether, and

[0026] 1-[6,7-dipropionate ammonium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl 1-[6',7'-dipropionate ammonium-1',3',5',8'-tetramethyl-4-vinyl-2-porphine]ethyl ether.

[0027] In certain embodiments, the porphyrin dimer salt is selected from the group consisting of DVDMS-1, DVDMS-2, DVDMS-3 and DVDMS-M (a mixture of DVDMS-1, DVDMS-2 and DVDMS-3).

[0028] In another aspect, the present application provides a method for treating cancer in an individual, comprising administering to the individual a therapeutically effective amount of a photosensitizer comprising a porphyrin dimer salt as disclosed herein, wherein the photosensitizer is administered in combination with an immune checkpoint inhibitor.

[0029] In some embodiments, the cancer is esophageal cancer. In some embodiments, the esophageal cancer can be divided by pathological classification, selected from esophageal squamous cell carcinoma (ESCC), adenocarcinoma, mucoepidermoid carcinoma, small cell carcinoma, large cell carcinoma, neuroendocrine tumor, adenosquamous carcinoma, undifferentiated carcinoma, optionally, esophageal squamous cell carcinoma (ESCC) or adenocarcinoma. In some embodiments, the esophageal cancer is advanced esophageal cancer, or optionally, locally advanced esophageal cancer. In some embodiments, the esophageal cancer is recurrent esophageal cancer (optionally, locally recurrent esophageal cancer) and / or metastatic esophageal cancer (optionally, distant metastatic esophageal cancer).

[0030] In certain embodiments, the individual has received radiation therapy and / or chemotherapy.

[0031] In certain embodiments, the individual has received prior treatment for the primary lesion and / or metastatic lesion.

[0032] In certain embodiments, the esophageal cancer exhibits resistance to at least one chemotherapy, and the chemotherapy drug is selected from the following group: taxane anti-tumor chemotherapy drugs, fluorouracil drugs, and platinum drugs. In certain embodiments, the taxane anti-tumor chemotherapy drugs are selected from the following group: paclitaxel and docetaxel. In certain embodiments, the fluorouracil drugs are selected from the following group: 5-fluorouracil, tegafur, and capecitabine. In certain embodiments, the platinum drugs are selected from the following group: cisplatin, carboplatin, and oxaliplatin.

[0033] In certain embodiments, the esophageal cancer exhibits resistance to immunotherapy.

[0034] In certain embodiments, the porphyrin dimer salt is administered in the range of 0.01-5 mg / kg body weight. In certain embodiments, the individual is subjected to photodynamic therapy using a laser 24-48 hours after administration of the porphyrin dimer salt. In certain embodiments, the wavelength of the laser is 631±3 nm, such as 630 nm, 631 nm or 632 nm. In certain embodiments, the dose of the laser is 90-300 J / cm 2 .

[0035] In certain embodiments, the immune checkpoint inhibitor is administered to the individual after a period of time after the laser is applied. In certain embodiments, the immune checkpoint inhibitor is administered to the individual 20 to 50 hours, preferably 24 to 48 hours after the laser is applied.

[0036] In certain embodiments, the immune checkpoint inhibitor is selected from the group consisting of PD-1 antagonists (PD-1 antibodies), PD-L1 antagonists (PD-L1 antibodies). In certain embodiments, the PD-1 antibody is selected from Pembrolizumab, Nivolumab, Cemiplimab, Toripalimab, Sintilimab, Camrelizumab, Tislelizumab, Penpulimab, Sepalimab, Serplulimab, and Putelimumab. In certain embodiments, the PD-L1 antibody is selected from Atezolizumab, Avelumab, Durvalumab, Envafolimab, and Sugemalimab.

[0037] In certain embodiments, the porphyrin dimer salt is sodium porphyrin (DVDMS), which is a sodium porphyrin dimer sodium salt bonded by an ether bond, and in some embodiments, the sodium porphyrin has the structure shown in the above formula (I), formula (II), or formula (III). In certain embodiments, the porphyrin dimer salt is DVDMS-1, DVDMS-2, DVDMS-3 or DVDMS-M (i.e., a mixture of DVDMS-1, DVDMS-2, and DVDMS-3), and the immune checkpoint inhibitor is pembrolizumab.

[0038] In yet another aspect, the present application also provides use of a photosensitizer as disclosed herein in the preparation of a medicament for treating esophageal cancer in an individual, wherein the treatment comprises the combined use of the photosensitizer and an immune checkpoint inhibitor.

[0039] Without wishing to be bound by theory, in the combined therapy of photodynamic therapy and immunotherapy based on porphyrin dimer salt photosensitizer described in the present application, the photodynamic therapy has the characteristics of neoadjuvant therapy such as intervention and combination in immunotherapy. The immunogenicity in the patient's body is first activated by photodynamic therapy, which provides a higher immune system foundation for subsequent immunotherapy means or drugs, strengthens the activity of immunotherapy cells, and improves the therapeutic effectiveness of the combined therapy. And the combined therapy described in the present application is suitable for the treatment of various types of cancer, especially esophageal cancer, especially for advanced esophageal cancer with poor front-line treatment effects. It provides a new systemic treatment method, and has a comprehensive inhibitory effect on primary and even systemic diffuse tumors, which is conducive to the effective removal of cancer cells and reduces the chance of cancer cell recurrence and / or metastasis. The combined therapy described in the present application can also be further combined with other treatment methods, such as after surgical treatment of the lesion, the combined therapy described in the present application is used for secondary intervention and clearance treatment to enhance the clearance rate of cancer cells, reduce the recurrence rate of tumors, and improve the survival rate of patients. DETAILED DESCRIPTION

[0040] The following description of the application is intended only to illustrate various embodiments of the application. Therefore, the specific modifications discussed should not be interpreted as limiting the scope of the application. It will be apparent to those skilled in the art that various equivalents, changes and modifications can be made without departing from the scope of the application, and it should be understood that these equivalent embodiments will be included herein. All references cited in this application, including publications, patents and patent applications, are incorporated into this application by reference in their entirety.

[0041] The present application provides a combination therapy of photodynamic therapy and immunotherapy based on porphyrin dimer salt photosensitizer for treating cancer in an individual, which comprises administering to the individual a therapeutically effective amount of a photosensitizer comprising a porphyrin dimer salt, the photosensitizer being used in combination with an immune checkpoint inhibitor. The combination therapy is suitable for treating various types of cancer, such as systemic or local recurrent and / or metastatic cancer, particularly esophageal cancer.

[0042] Esophageal cancer

[0043] As used herein, the terms "cancer", "malignancy", "tumor" and "cancer" are used interchangeably herein to refer to cells that exhibit relatively abnormal, uncontrolled and / or autonomous growth, such that the cells exhibit an abnormal growth phenotype characterized by significantly uncontrolled cell proliferation. As used herein, the terms "cancer", "malignancy", "tumor" and "cancer" may include primary, or metastatic.

[0044] The term "esophageal cancer" refers to a tumor that occurs in the esophageal epithelial tissue. According to pathological classification, esophageal cancer includes but is not limited to: esophageal squamous cell carcinoma (ESCC), adenocarcinoma, mucoepidermoid carcinoma, small cell carcinoma, large cell carcinoma, neuroendocrine tumor, adenosquamous carcinoma, or undifferentiated carcinoma. In some embodiments, the esophageal cancer is esophageal squamous cell carcinoma (ESCC) or adenocarcinoma.

[0045] In some embodiments, the esophageal cancer described herein includes advanced esophageal cancer. In some embodiments, the esophageal cancer is locally advanced esophageal cancer.

[0046] According to the scope of cancer invasion, the esophageal cancer stage is determined according to the TNM staging standard. Generally speaking, in oncology, esophageal cancer in TNM stage I and II is determined as early esophageal cancer, and TNM stage III and IV are determined as advanced esophageal cancer or locally advanced esophageal cancer. The term "locally advanced esophageal cancer" generally refers to esophageal cancer that has invaded the esophagus and surrounding tissues, but there is no invasion of important organs and no distant metastasis. In some embodiments, the locally advanced esophageal cancer includes esophageal cancer that has failed first-line treatment, second-line treatment, or even third-line treatment, for example, with the following characteristics: lymph node and distant metastasis already exist, the patient's basic physical condition is poor, and treatment methods aimed at radical treatment can no longer be achieved.

[0047] The term "first-line treatment" refers to the first round of treatment after diagnosis, which is the most effective and has the fewest side effects. It is also called basic treatment or therapy. The goal of treatment is to effectively inhibit tumor progression when possible. The term "second-line treatment" refers to the situation where the patient's tumor progresses again after first-line treatment and is resistant to the first-line treatment, and a different anti-cancer treatment mechanism is needed. The term "third-line treatment" refers to the treatment that is switched to another treatment after the failure of second-line treatment. Usually, there are fewer drugs and effective treatment options.

[0048] In some embodiments, the esophageal cancer is recurrent esophageal cancer. In some embodiments, the esophageal cancer is locally recurrent esophageal cancer. The term "recurrent esophageal cancer" refers to the recurrence of a tumor of the same type as the primary esophageal tumor after the esophageal tumor at the primary site has regressed after treatment. In some embodiments, the recurrent esophageal cancer is systemically recurrent esophageal cancer or locally recurrent esophageal cancer.

[0049] In some embodiments, the esophageal cancer is metastatic esophageal cancer. In some embodiments, the esophageal cancer is distant metastatic esophageal cancer. The term "metastatic esophageal cancer" refers to the situation in which, in addition to the primary esophageal lesion, metastases to adjacent sites or distant organs through the lymph or blood, respectively. The term "distant metastatic esophageal cancer" refers to metastasis that spreads to a distance away from the primary esophageal cancer lesion. For example, esophageal cancer that was originally in the lower esophagus metastasizes to the supraclavicular lymph nodes, which can be considered as distant metastatic esophageal cancer that has metastasized to distal lymph nodes. For another example, if esophageal cancer that was originally in the neck metastasizes to the lymph nodes in the neck, it can be considered as a metastasis to the proximal lymph nodes.

[0050] In some embodiments, the recurrent or metastatic esophageal cancer has caused esophageal obstruction, making it impossible for the patient to eat and drink independently. One of the current primary treatments for this type of esophageal cancer is to open up the esophageal passage, improve the patient's difficulty in eating, and increase the patient's nutritional needs, which is beneficial to strengthen the effect of palliative treatment. At present, in addition to palliative radiotherapy and chemotherapy, the primary treatment options for opening up the esophageal passage include physical treatments such as ablation of esophageal stents, surgical electrosurgical resection, and balloon dilatation. However, all of the above methods have major drawbacks and can only play a short-term physical expansion role. It cannot solve the recurrence and blockage of esophageal cancer in the esophageal duct and cannot really play a role in clearing cancer cells in the esophagus. The combined therapy of photodynamic therapy and immunotherapy based on porphyrin dimer salt photosensitizer described in this application can unexpectedly effectively solve the above problems. On the one hand, with the help of a large amount of accumulation of photosensitizers in the tumor, tumor cells can be killed by photodynamic therapy under light of a specific wavelength. On the other hand, after photodynamic therapy destroys tumor cells, it can release a large amount of tumor antigens, which will preferentially activate the immune response in the patient's body and improve the basis of the immune system. The inventors of the present application have discovered that when combined with subsequent immunotherapy methods or drugs, the activity of immune cells can be significantly enhanced, and the effectiveness of patient treatment can be improved, thereby solving the problem of esophageal cancer causing esophageal obstruction, fundamentally inhibiting the chance of tumor recurrence, and solving the problem of self-feeding for patients. It greatly improves the patient's life treatment and nutritional support, and also lays a good treatment foundation for subsequent palliative treatment, which is beneficial to the continuation of the patient's survival.

[0051] In some embodiments, the esophageal cancer described in the present application also includes esophageal cancer that shows resistance to at least one of immunotherapy and chemotherapy. In the present application, "drug resistance" refers to that after a certain period of treatment, a drug resistance mechanism for therapeutic agents (such as immunotherapy and / or chemotherapy) has been produced in the patient's body, resistance or non-response occurs, and the efficacy of the drug cannot be benefited again. For example, even if the treatment of the therapeutic agent is accepted, the number of tumor cells still increases. The drug resistance can be that which occurs before treatment (i.e., primary), or that which is produced after treatment (i.e., acquired, or recurrent). It is not desirable to be bound by theory, and the porphyrin dimer salt described in the present application belongs to porphyrin photosensitizer, and porphyrin is a necessary substance in the synthesis process of human erythrocytes, and there are a large number of porphyrin substances in the human body, so after the porphyrin photosensitizer runs in the body, the immune system is insensitive to porphyrin drugs, lacks a drug resistance mechanism, and thus the photosensitizer described in the present application can be used for single, multiple, or even high-frequency treatment without losing the effectiveness of tumor treatment. Therefore, the combined therapy described in the present application is not easy to produce drug resistance in the patient's body and can still exert its effect stably after a certain period of use.

[0052] In some embodiments, the esophageal cancer described herein exhibits resistance to one or more chemotherapeutic agents.

[0053] "Chemotherapy" herein refers to biological (macromolecules) or chemical (small molecules) compounds that can be used to treat cancer. The types of chemotherapy drugs include, but are not limited to: histone deacetylase inhibitors (HDACI), alkylating agents, antimetabolites, alkaloids, cytotoxic / anticancer antibiotics, topoisomerase inhibitors, tubulin inhibitors, proteins, antibodies, kinase inhibitors, etc. Chemotherapy drugs include compounds used for targeted therapy and compounds for non-targeted conventional chemotherapy.

[0054] In some embodiments, the esophageal cancer exhibits resistance to at least one chemotherapy, and the chemotherapy may be any conventional chemotherapy known in the art or standard chemotherapy in the clinic, including but not limited to the following drugs or combinations thereof: taxane anti-tumor chemotherapy drugs, fluorouracil drugs, platinum drugs, antifolate drugs, topoisomerase inhibitors. Examples of taxane anti-tumor chemotherapy drugs include, for example, paclitaxel compounds and docetaxel compounds. Examples of fluorouracil drugs include, for example, 5-fluorouracil, Tegafur (i.e., a combination of tegafur, gimeracil and oteracil), capecitabine, etc. Examples of platinum drugs include, for example, cisplatin, carboplatin, oxaliplatin, nedaplatin, etc. Examples of antifolate drugs include, methotrexate, pemetrexed, etc. Examples of topoisomerase inhibitors include irinotecan.

[0055] In some embodiments, the esophageal cancer includes but is not limited to showing resistance to at least one chemotherapy drug regimen selected from the following groups: commonly used chemotherapy regimens for advanced ESCC, including cisplatin combined with fluorouracil or paclitaxel combined with platinum drugs, etc.; commonly used chemotherapy regimens for advanced esophageal gastric junction adenocarcinoma, including cisplatin or oxaliplatin combined with fluorouracil drugs, etc.; first-line treatment regimens for esophageal cancer patients with good physical condition, including a three-drug combination regimen of taxanes combined with platinum and fluorouracil drugs.

[0056] In some embodiments, the esophageal cancer described herein exhibits resistance to one or more immunotherapies.

[0057] "Immunotherapy" in this article refers to a treatment method that uses the patient's own immune cells to eliminate cancer by enhancing and activating the function of immune cells. Examples of immunotherapy include, but are not limited to: molecular targeted therapy; immune checkpoint inhibitors (such as PD-1 / L1 inhibitors and CTLA-4 inhibitors); adoptive immune cell therapy (such as CAR-T, TIL, NK, CIK / DC-CIK); cytokine therapy; or tumor vaccines.

[0058] In some embodiments, the esophageal cancer described herein exhibits resistance to an immune checkpoint inhibitor.

[0059] The term "immune checkpoint inhibitor" in this article refers to drugs that can target immune checkpoint molecules, relieve the inhibition of tumor cells on immune cells, and prompt immune cells to reactivate and recognize / kill cancer cells.

[0060] In some embodiments, the immune checkpoint inhibitor is a PD-1 antagonist (PD-1 antibody) or a PD-L1 antagonist (PD-L1 antibody).

[0061] In some embodiments, the PD-1 antibody includes but is not limited to: Pembrolizumab, Nivolumab, Cemiplimab, Toripalimab, Sintilimab, Camrelizumab, Tislelizumab, Penpulimab, Sepalimab, Serplulimab and Putelimumab.

[0062] In some embodiments, the PD-L1 antibodies include but are not limited to Atezolizumab, Avelumab, Durvalumab, Envafolimab and Sugemalimab.

[0063] In some embodiments, the esophageal cancer described herein exhibits resistance to at least one immunotherapy.

[0064] In some embodiments, the esophageal cancer described herein shows resistance to at least one of the PD-L1 antibodies or PD-1 antibodies.

[0065] In some embodiments, the resistance to immunotherapy can be any conventional immunotherapy regimen known in the art or a clinical standard immunotherapy regimen, including but not limited to the following drug regimens: a second-line treatment drug regimen for patients with advanced esophageal squamous cell carcinoma (ESCC) who have failed first-line chemotherapy, such as carrelizumab or tislelizumab; a second-line treatment drug regimen for ESCC patients with PD-L1 CPS>10 who have failed first-line chemotherapy, such as pembrolizumab monotherapy; a third-line and subsequent treatment drug regimen for patients with esophageal gastric junction adenocarcinoma who have failed at least two lines of chemotherapy, such as nivolumab; a third-line and subsequent treatment drug regimen for HER-2-positive advanced esophageal gastric junction cancer, such as Disitamab, an antibody-drug conjugate targeting HER-2. Vedotin); for patients with advanced esophageal gastric junction cancer, the third-line and subsequent treatment drug regimens include, for example, the anti-angiogenic targeted drug apatinib; for patients with advanced ESCC, the second-line and subsequent treatment drug regimens include, for example, anlotinib or apatinib.

[0066] In some embodiments, the esophageal cancer described herein is esophageal cancer that exhibits resistance to combined treatment with immunotherapy and chemotherapy.

[0067] In some embodiments, the esophageal cancer includes but is not limited to showing resistance to the following combined treatment drug regimen: a first-line treatment regimen for patients with HER-2-positive advanced esophageal gastric junction adenocarcinoma, comprising combining trastuzumab with cisplatin and fluorouracil.

[0068] In some embodiments, the individual suffering from the esophageal cancer (eg, an individual exhibiting drug resistance) has received radiation therapy and / or chemotherapy.

[0069] In some embodiments, the individual suffering from the esophageal cancer (eg, an individual exhibiting drug resistance) has previously received treatment for the primary lesion or metastatic lesions.

[0070] Photosensitizer

[0071] The photosensitizer herein includes a porphyrin dimer salt. In the present application, a porphyrin dimer salt refers to a compound structure having two porphyrin structures connected by covalent bonding or a linker.

[0072] In some embodiments, the porphyrin dimer salt has a structure shown in the following formula (I), formula (II), or formula (III):

[0073]

[0074]

[0075] in

[0076] R is independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy and C 1-6 acyl, which is optionally substituted by one or more substituents selected from halogen and hydroxy,

[0077] M is an alkali metal, an alkaline earth metal or NH4 + ,

[0078] p is the reciprocal of the valence of M,

[0079] and solvates thereof, especially hydrates.

[0080] In this application, “C 1-6 "Alkyl" means a branched or straight-chain monovalent saturated hydrocarbon group having 1 to 6 carbon atoms. 1-4 Alkyl. Examples include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, and n-hexyl.

[0081] In this application, “C 2-6 "Alkenyl" means a straight or branched monovalent unsaturated hydrocarbon group having 2 to 6 carbon atoms and containing one or more double bonds. 2-4 Examples include, but are not limited to, vinyl, prop-1-enyl, allyl, but-1-enyl, pent-1-enyl, pent-1,4-dienyl, and the like.

[0082] In this application, “C 2-6"Alkynyl" means a straight or branched monovalent unsaturated hydrocarbon group having 2 to 6 carbon atoms and containing one or more triple bonds. 2-4 Examples include, but are not limited to, ethynyl, prop-1-ynyl, prop-2-ynyl, but-1-ynyl, pent-1-ynyl, pent-1,3-diynyl, and the like.

[0083] In this application, “C 1-6 "Alkoxy" means a group R'-O-, wherein R' is a C 1-6 Alkyl. Preferably C 1-4 Alkoxy. Examples include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, isopentoxy, neopentoxy, and n-hexoxy.

[0084] In this application, “C 1-6 "Acyl" means a group R'-C(O)-, wherein R' is H or a branched or straight-chain monovalent saturated hydrocarbon radical having 1 to 5 carbon atoms. Preferably C 1-4 Acyl. Examples include, but are not limited to, formyl, acetyl, propionyl, butyryl, valeryl, hexanoyl, and the like.

[0085] In this application, "optional" or "optionally" means that the event or situation described later can occur but does not have to occur, and the description includes situations where the event or situation occurs and situations where it does not occur. For example, "C 1-6 "alkyl..., which is optionally substituted by one or more substituents selected from halogen and hydroxy" means a C alkyl group which may be, but not necessarily, substituted by one or more halogen and / or hydroxy. 1-6 Alkyl, this description includes unsubstituted C 1-6 Alkyl and C substituted by one or more halogen and / or hydroxyl 1-6 alkyl.

[0086] In the present application, "halogen" means fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine and bromine, more preferably fluorine and chlorine.

[0087] In this application, "hydroxy" means the group -OH.

[0088] In this application, "valence" means the number of shared electron pairs formed by one atom of a chemical element. The valence of an ion is equal to its charge. For example, alkali metals and NH4 + The valence number of is 1, and the valence number of alkaline earth metals is 2.

[0089] In the present application, "solvate" means a solvent addition form formed by the addition of solvent molecules to the porphyrin dimer salts described herein which are bonded together by mutual attraction. If the solvent is water, the solvate formed is a hydrate, such as a monohydrate or a dihydrate; if the solvent is an alcohol, the solvate formed is an alcoholate, such as an addition form with methanol or ethanol.

[0090] In some embodiments, R is independently selected from C optionally substituted with one or more hydroxyl groups. 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 1-6 Acyl, M is an alkali metal or NH4 + , and p is 1.

[0091] In some embodiments, R is independently selected from -CH=CH 2 、-CH(OH)CH 3 and-COCH 3 , M is an alkali metal or NH4 + , and p is 1.

[0092] In some embodiments, R is independently selected from -CH=CH2 and -CH(OH)CH 3 , M is an alkali metal or NH4 + , and p is 1.

[0093] In some embodiments, M is an alkali metal.

[0094] In some embodiments, M is Na or K.

[0095] In some embodiments, the porphyrin dimer salt bound by an ether bond is selected from: di[1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl]ether, di[1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl]ether, 1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl1-[6',7'-sodium dipropionate-1',3',5',8'-tetramethyl-4-vinyl-2-porphine]ethylether, di[1-[potassium 6,7-dipropionate-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl]ether, di[1-[potassium 6,7-dipropionate-1,3,5,8-tetramethyl-2- Vinyl-4-porphine]ethyl]ether, 1-[6,7-dipropionate potassium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl 1-[6',7'-dipropionate potassium-1',3',5',8'-tetramethyl-4-vinyl-2-porphine]ethyl ether, di[1-[6,7-dipropionate ammonium-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl 1-[6,7-dipropionate-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl] ether, di[1-[6,7-dipropionate-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl] ether, and 1-[6,7-dipropionate-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl 1-[6',7'-dipropionate-1',3',5',8'-tetramethyl-4-vinyl-2-porphine]ethyl ether.

[0096] In some embodiments, the porphyrin dimer salt is DVDMS, which is a sodium salt of a porphyrin dimer bonded by an ether bond. In some embodiments, DVDMS has the structure shown in the above formula (I), formula (II) or formula (III).

[0097] In some embodiments, the porphyrin dimer salt is di[1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl]ether (DVDMS-1), di[1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl]ether (DVDMS-2), 1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl 1-[6',7'-sodium dipropionate-1',3',5',8'-tetramethyl-4-vinyl-2-porphine]ethyl ether (DVDMS-3), or a mixture of the above three (DVDMS-M).

[0098]

[0099]

[0100] More information about the photosensitizer comprising a porphyrin dimer salt is described in CN102030765B, the disclosure of which is incorporated herein in its entirety.

[0101] Combination therapy

[0102] The present application provides a combination therapy of photodynamic therapy and immunotherapy based on a porphyrin dimer salt photosensitizer for treating cancer in an individual, which comprises administering a therapeutically effective amount of a porphyrin dimer salt photosensitizer to the individual, wherein the photosensitizer is used in combination with an immune checkpoint inhibitor.

[0103] In the present application, the term "combination therapy" means that when two or more drugs are used in combination, they can be administered simultaneously, in overlapping time periods or sequentially. The administration routes of the two drugs administered in combination can be the same or different.

[0104] In this application, the term "treatment" means to alleviate one or more disease-related symptoms, delay or avoid disease progression or deterioration, or cure a disease. For cancer (e.g., esophageal cancer), treatment may include curbing cancer development, reducing its severity, delaying its growth, inhibiting its metastasis, and reducing recurrence, etc. However, treatment does not require that the disease or symptoms associated therewith be completely eliminated.

[0105] In this application, the term "individual" means an animal, including mammals and non-mammals. Mammals refer to any member of the mammal class, including but not limited to humans, non-human primates (such as chimpanzees and other apes and monkeys), farm animals (such as cattle, horses, sheep, goats and pigs), domestic animals (such as rabbits, dogs and cats), laboratory animals (including rodents, such as rats, mice and guinea pigs), etc. Examples of non-mammals include but are not limited to birds, etc.

[0106] As used herein, the term "therapeutically effective amount" means an amount of a compound or combination therapy of the invention that produces the biological or medical response sought or desired by a researcher or clinician.

[0107] In the present application, the photosensitizer disclosed herein can be formulated into any suitable form and can be applied by any suitable route, can be formulated into solutions, suspensions, emulsions, lyophilized preparations, etc. for injection (e.g., intra-arterial, intravenous, intramuscular, subcutaneous, intraperitoneal injection, etc.) or infusion administration, formulated into tablets, solutions, capsules, etc. for oral administration, formulated into ointments, creams, suppositories, patches, etc. for topical administration, formulated into aerosols, sprays, powders, etc. for inhalation administration. Preferred modes of administration are generally injection infusion, oral and topical administration. Injection / infusion administration can allow the compound of the present invention to quickly reach distribution equilibrium, for example, within 24 hours.

[0108] In certain embodiments, the porphyrin dimer salt is administered in the range of 0.01-5 mg / kg body weight, for example, 0.05-4 mg / kg body weight, 0.1-2 mg / kg body weight, or 0.2 mg-1 mg / kg body weight.

[0109] In some embodiments, the porphyrin dimer salt is used to perform photodynamic therapy on the individual using a laser for a period of time after administration. Preferably, the porphyrin dimer salt is used to perform photodynamic therapy on the individual using a laser 24-48 hours, especially 24 hours after administration. In some embodiments, the wavelength of the laser is 631±3nm, such as 630nm, 631nm or 632nm. In some embodiments, the dose of the laser is 60-300J / cm 2 , 70-300J / cm 2 、80-300J / cm 2 、90-300J / cm 2 、90-290J / cm 2 、90-280J / cm 2 、90-270J / cm 2 、90-260J / cm 2 、90-250J / cm 2 、90-240J / cm 2 、90-230J / cm 2 、90-220J / cm 2 、90-210J / cm 2 、90-200J / cm 2 、90-190J / cm 2 、90-180J / cm 2 、90-170J / cm 2 、90-160J / cm 2 , 90-150J / cm 2 、90-140J / cm 2 、90-130J / cm 2 、90-120J / cm 2 100-120J / cm 2 , 100-110J / cm 2 , preferably, 90-300 J / cm 2 In some embodiments, for advanced esophageal cancer that has caused near-complete obstruction, the laser dose is 200 J / cm 2 .

[0110] In this application, "immune checkpoint inhibitors" refer to drugs that can target immune checkpoint molecules, relieve the inhibition of tumor cells on immune cells, and prompt immune cells to reactivate and recognize / kill cancer cells.

[0111] In some embodiments, the immune checkpoint inhibitor is a PD-1 antagonist (PD-1 antibody) or a PD-L1 antagonist (PD-L1 antibody).

[0112] In some embodiments, the PD-1 antibody includes but is not limited to: Pembrolizumab, Nivolumab, Cemiplimab, Toripalimab, Sintilimab, Camrelizumab, Tislelizumab, Penpulimab, Sepalimab, Serplulimab and Putelimumab.

[0113] In some embodiments, the PD-L1 antibodies include but are not limited to Atezolizumab, Avelumab, Durvalumab, Envafolimab and Sugemalimab.

[0114] In some embodiments, the immune checkpoint inhibitor is administered to the individual after a period of photodynamic therapy. In some embodiments, the immune checkpoint inhibitor is administered to the individual 20 to 50 hours, especially 24 to 48 hours after the laser is applied. In some embodiments, compared with the DVDMS-PDT alone treatment, the combination of DVDMS-PDT and PD-1 antibody can significantly reduce the tumor growth rate in the mouse model and has a significantly enhanced anti-tumor effect. In some embodiments, PD-1 antibody treatment between 24 hours and 48 hours after DVDMS-PDT has a more excellent anti-tumor effect, with a tumor inhibition rate of more than 98%.

[0115] In certain embodiments, the porphyrin dimer salt is DVDMS-1, DVDMS-2, DVDMS-3 or DVDMS-M, and the immune checkpoint inhibitor is a PD-1 antibody, such as pembrolizumab.

[0116] Example

[0117] Material:

[0118] 1. Test drugs and instruments

[0119] 1.1 Test drugs

[0120] DVDMS-2 sodium porphyrin for injection (Shanghai Guangsheng Pharmaceutical Co., Ltd.);

[0121] Pembrolizumab (purchased from Merck).

[0122] 1.2 Lighting equipment

[0123] 630nm semiconductor laser therapy device (XINGDA PDT 630II), laser wavelength meter (THORLABS), laser power meter (PM310D), equipped with Microlens optical fiber.

[0124] 2. Tumor cell lines

[0125] Human esophageal cancer Eca-109 cell line was purchased from China Center for Type Culture Collection (CCTCC) in Wuhan.

[0126] 3. Experimental Animals

[0127] Nu / nu nude mice, weighing 18-22 g, female, were provided by Shanghai Slake Experimental Animal Co., Ltd.

[0128] Example 1. Efficacy of DVDMS-PDT combined with PD-1 antibody in the human esophageal cancer Eca-109 mouse model

[0129] Objective: To observe the inhibitory effect of DVDMS-PDT combined with PD-1 antibody (pembrolizumab) on the growth of human esophageal cancer Eca-109 xenograft tumors in nude mice, optimize the time window between DVDMS-PDT and PD-1 antibody treatment, and provide a reference for clinical application.

[0130] plan:

[0131] 1. Preparation of human esophageal cancer model

[0132] Human esophageal cancer Eca-109 cells in the logarithmic growth phase were collected and diluted to 5*10 7 The concentration of cells / mL was 0.1 mL per nude mouse, and injected subcutaneously at the right thigh root of the nude mouse. After 7-10 days, when the tumor grew to a diameter of about 5-8 mm, it was ready for use.

[0133] 2. Study the effect of PD-1 antibody treatment at different time windows after DVDMS-PDT on tumor growth

[0134] Select the qualified tumor-bearing mouse model as described above, measure the length and width of the tumor with a vernier caliper, and stratify and group the mice according to the size of the tumor, with 6 mice in each group. The injection of sodium porphyrin DVDMS-2 was prepared 24 hours before the experiment and refrigerated in the dark before use. DVDMS-2 was administered through the tail vein at a dose of 2 mg / kg body weight (Day-1), and PDT treatment was performed 24 hours later (Day 0). When implementing tumor illumination, first adjust the 630nm semiconductor laser used so that the output power of the optical fiber end is locked at 250mW, and then the optical fiber with a microlens at the end is facing the target site, so that the laser is projected vertically and completely covers the tumor, and the spot diameter is kept at 10mm. The therapeutic laser dose is about 70J / cm 2 .

[0135] PD-1 antibody (pembrolizumab) was administered again after a period of time after the end of DVDMS-PDT. According to the experimental groups, each group was treated with PD-1 antibody at the time intervals shown in Table 1.

[0136] After the combined treatment, the tumor growth and toxicity of the animals were observed. Except for the tumor illumination link, the mice were strictly protected from light for 3 days after the tail vein administration, and then changed to low light feeding. The animals were killed on Day 21 after DVDMS-PDT, the tumors were removed, the tumor weight was weighed, the tumor inhibition effect of each group was evaluated, and the tumor growth inhibition rate of the drug was calculated. The evaluation index was the relative tumor proliferation rate T / C (%), and the calculation formula was:

[0137] T / C (%) = [RTV of treatment group (T) / RTV of negative control group (C)] × 100%.

[0138] Table 1

[0139]

[0140] Conclusion: As shown in Table 1, compared with the DVDMS-PDT alone, the combination of DVDMS-PDT and PD-1 antibody can significantly reduce the tumor growth rate in the mouse model and has a significantly enhanced anti-tumor effect. And 24-48 hours after DVDMS-PDT is a more preferred window period for immunotherapy. The results showed that the treatment effect was better than that of the control group less than 24 hours or more than 48 hours after DVDMS-PDT. In addition, the effect of PD-1 antibody treatment between 24 hours and 48 hours after DVDMS-PDT was even better, and the tumor inhibition rate could reach more than 98%. In addition, no obvious toxicity was observed in the animals in each group treated.

[0141] Example 2. Therapeutic effect of DVDMS-PDT combined with PD-1 antibody in clinical cases of advanced esophageal cancer

[0142] The patient, 80 years old, had advanced esophageal cancer and was diagnosed with abnormal swallowing. The pathological diagnosis was esophageal squamous cell carcinoma, high-grade intraepithelial neoplasia with focal infiltration, lymph node and distal metastasis, and pathological stage: T4N3M1. He had undergone six cycles of systemic chemotherapy (paclitaxel + cisplatin), but his condition still showed obvious progression, and his esophagus was almost completely obstructed and he could not eat. According to the esophageal cancer treatment guidelines, there was no recommended treatment plan, and the expected survival period was three to six months.

[0143] In order to improve the patient's esophageal obstruction, thereby improving the patient's eating condition and improving the patient's quality of life, the researchers used the combination therapy of DVDMS-PDT and PD-1 antibody (pembrolizumab) described in this application on the patient.

[0144] plan:

[0145] The patients were given DVDMS-2 at a dose of 0.2 mg / kg body weight, and PDT treatment was performed 24 hours later. The wavelength of the treatment light was 630±3 nm and the treatment light dose was 200 J / cm 2 . The patient was given pembrolizumab for immunotherapy 24 hours after PDT treatment, with a dose of 200 mg each time. Subsequently, pembrolizumab was continuously administered once every three weeks.

[0146] After one week of combined DVDMS-PDT and PD-1 antibody treatment, the patient's esophageal obstruction was greatly relieved and he could eat semi-liquid food. The patient continued to use pembrolizumab for six times, and the disease was in a stable state. Later, the patient stopped receiving treatment for personal reasons. Long-term follow-up showed that he was still alive in the fourth year.

[0147] Conclusion: The combination of DVDMS-PDT and PD-1 antibody has the effect of systemically controlling disease progression, inhibiting tumor recurrence and spread, and improving patients' eating conditions for patients with advanced esophageal cancer, especially those in the terminal stage. It is beneficial to the extension of patients' survival and improves their quality of life.

[0148] Example 3. Clinical trial of DVDMS-PDT combined with immunotherapy drugs

[0149] Participants: Patients aged ≥18 years with histologically confirmed esophageal squamous cell carcinoma (ESCC), radiologically confirmed metastatic esophageal cancer, and who had failed at least one line of metastatic systemic therapy.

[0150] Regimen: Patients who met the above criteria received intravenous injection of DVDMS-2 (Day-1), received PDT for the primary ESCC lesion 24 hours after the administration of DVDMS-2 (Day 0), received immunotherapy with a fixed dose of 200 mg of PD-1 antibody (e.g., pembrolizumab or other selected PD-1 antibody or PD-L1 antibody) intravenously 24 hours after DVDMS-PDT (Day 1), and then received immunotherapy once every 21 days (one immunotherapy cycle every 21 days) for 8 cycles.

[0151] On the 30th day (Day 30) after DVDMS-PDT, esophagogastroscopy (OGD) was performed to evaluate the efficacy of the treatment of the primary lesions and to determine whether DVDMS-PDT was necessary again.

[0152] Expected results:

[0153] 1. The primary site of ESCC that receives DVDMS-PDT will produce new antigens, which will enhance the effect of immunotherapy and enhance the inhibitory effect on tumor growth, metastasis, and recurrence;

[0154] 2. The combination of DVDMS-PDT and immunotherapy drugs can enhance the efficacy of immunotherapy on primary lesions and metastatic lesions, and improve the objective response rate (ORR) and duration of response (DOR);

[0155] 3. The combination of DVDMS-PDT and immunotherapy drugs can improve the quality of life (QoL) of ESCC patients;

[0156] 4. The combination of DVDMS-PDT and immunotherapy drugs can prolong the progression-free survival (PFS) of ESCC patients;

[0157] 5. The combination of DVDMS-PDT and immunotherapy drugs can prolong the overall survival (OS) of ESCC patients.

[0158] While the present application has been particularly shown and described with reference to specific embodiments, some of which are preferred embodiments, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present application disclosed herein.

Claims

1. A method for treating cancer in an individual, comprising administering to the individual a therapeutically effective amount of a photosensitizer comprising a porphyrin dimer salt, the photosensitizer being administered in combination with an immune checkpoint inhibitor, optionally wherein the cancer is esophageal cancer.

2. The method of claim 1, wherein the esophageal cancer is selected from the group consisting of esophageal squamous cell carcinoma (ESCC), adenocarcinoma, mucoepidermoid carcinoma, small cell carcinoma, large cell carcinoma, neuroendocrine tumor, adenosquamous carcinoma, and undifferentiated carcinoma, optionally, the esophageal cancer is esophageal squamous cell carcinoma (ESCC) or adenocarcinoma.

3. The method of claim 1, wherein the esophageal cancer is advanced esophageal cancer, or alternatively, locally advanced esophageal cancer.

4. The method of claim 1, wherein the esophageal cancer is recurrent esophageal cancer, optionally, locally recurrent esophageal cancer, and / or metastatic esophageal cancer, optionally, distant metastatic esophageal cancer.

5. The method according to any one of claims 1 to 4, wherein the esophageal cancer exhibits resistance to at least one chemotherapy drug, and the chemotherapy drug is selected from the following group: taxane anti-tumor chemotherapy drugs, fluorouracil drugs or platinum drugs.

6. The method according to claim 5, wherein the taxane anti-tumor chemotherapy drug is selected from the group consisting of paclitaxel or docetaxel.

7. The method according to claim 5, wherein the fluorouracil drug is selected from the group consisting of 5-fluorouracil, S-1, or capecitabine.

8. The method according to claim 5, wherein the platinum drug is selected from the group consisting of cisplatin, carboplatin or oxaliplatin.

9. The method according to any one of claims 1-4, wherein the esophageal cancer exhibits resistance to immunotherapy.

10. The method according to any preceding claim, wherein the individual has received radiotherapy and / or chemotherapy.

11. The method according to any preceding claim, wherein the individual has previously received treatment for primary lesions and / or metastatic lesions.

12. A method according to any preceding claim, wherein the porphyrin dimer salt has a structure shown in formula (I), formula (II) or formula (III): in R is independently selected from C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy and C 1-6acyl, which is optionally substituted by one or more substituents selected from halogen and hydroxy, M is an alkali metal, an alkaline earth metal or NH4 + , p is the reciprocal of the valence number of M.

13. The method according to claim 12, wherein R is independently selected from C optionally substituted by one or more hydroxyl groups. 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl and C 1-6 Acyl, M is an alkali metal or NH4 + , and p is 1.

14. The method according to claim 13, wherein R is independently selected from -CH=CH2, -CH(OH)CH3 and -COCH3, and M is an alkali metal or NH4 + , and p is 1.

15. The method according to claim 14, wherein R is independently selected from -CH=CH2 and -CH(OH)CH3, and M is an alkali metal or NH4 + , and p is 1.

16. A process according to any one of claims 12 to 15, wherein M is an alkali metal.

17. The method of claim 16, wherein M is Na or K.

18. The method according to claim 12, wherein the porphyrin dimer salt bound by an ether bond is selected from Bis[1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl]ether, Bis[1-[sodium 6,7-dipropionate-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl]ether, 1-[6,7-dipropionic acid sodium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl 1-[6',7'-dipropionic acid sodium-1', 3',5',8'-Tetramethyl-4-vinyl-2-porphine]ethyl ether, Bis[1-[6,7-dipropanoic acid potassium-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl]ether, Bis[1-[6,7-dipropanoic acid potassium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl]ether, 1-[6,7-dipropionate potassium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl 1-[6',7'-dipropionate potassium-1', 3',5',8'-Tetramethyl-4-vinyl-2-porphine]ethyl ether, Bis[1-[6,7-dipropionate ammonium-1,3,5,8-tetramethyl-4-vinyl-2-porphine]ethyl]ether, Bis[1-[6,7-dipropionate ammonium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl]ether, and 1-[6,7-dipropionate ammonium-1,3,5,8-tetramethyl-2-vinyl-4-porphine]ethyl 1-[6',7'-dipropionate ammonium-1', 3',5',8'-Tetramethyl-4-vinyl-2-porphine]ethyl ether.

19. The method according to any one of claims 12 to 18, wherein the porphyrin dimer salt is administered in the range of 0.01-5 mg / kg body weight.

20. The method according to any preceding claim, wherein the subject is subjected to photodynamic therapy using laser light 24-48 hours after administration of the porphyrin dimer salt.

21. The method according to claim 20, wherein the wavelength of the laser light is 631±3 nm, such as 630 nm, 631 nm or 632 nm.

22. The method according to claim 20 or 21, wherein the laser dose is 90-300 J / cm 2 .

23. The method of any preceding claim, wherein the immune checkpoint inhibitor is administered to the individual a period of time after the laser application.

24. The method of claim 23, wherein the immune checkpoint inhibitor is administered to the individual 20 to 50 hours (optionally 24 to 48 hours) after the laser administration.

25. The method according to claim 23 or 24, wherein the immune checkpoint inhibitor is selected from the group consisting of a PD-1 antagonist and a PD-L1 antagonist, wherein the PD-1 antagonist is optionally a PD-1 antibody, and the PD-L1 antagonist is optionally a PD-L1 antibody.

26. The method of claim 25, wherein the PD-1 antibody comprises Pembrolizumab, Nivolumab, Cemiplimab, Toripalimab, Sintilimab, Camrelizumab, Tislelizumab, Penpulimab, Sepalimab, Serplulimab and Putelimumab.

27. The method of claim 25, wherein the PD-L1 antibodies include Atezolizumab, Avelumab, Durvalumab, Envafolimab, and Sugemalimab.

28. The method of any preceding claim, wherein the porphyrin dimer salt is DVDMS-1, DVDMS-2, DVDMS-3 or DVDMS-M, and wherein the immune checkpoint inhibitor is pembrolizumab.

29. Use of a photosensitizer comprising a porphyrin dimer salt as defined in claims 12 to 18 in the preparation of a medicament for treating esophageal cancer in an individual, the treatment comprising the combination of the photosensitizer and an immune checkpoint inhibitor, optionally wherein the cancer or the individual is as defined in claims 1-11.

30. A photosensitizer suitable for treating cancer in an individual, wherein the photosensitizer comprises a porphyrin dimer salt as defined in claims 12 to 18, and the photosensitizer is administered in combination with an immune checkpoint inhibitor.

31. The photosensitizer according to claim 30, wherein the immune checkpoint inhibitor is as defined in claims 25 to 27.

32. The photosensitizer according to claim 30 or 31, wherein the porphyrin dimer salt is administered in the range of 0.01-5 mg / kg body weight.

33. The photosensitizer according to any one of claims 30 to 32, wherein the subject is subjected to photodynamic therapy using laser light 24 hours after administration of the porphyrin dimer salt.

34. The photosensitizer according to claims 30-33, wherein the wavelength of the laser is 631±3 nm, such as 630 nm, 631 nm or 632 nm.

35. The photosensitizer according to claim 33-34, wherein the dose of the laser is 90-300 J / cm 2 .

36. The photosensitizer of claims 33-35, wherein the immune checkpoint inhibitor is administered to the individual a period of time after the laser application.

37. A photosensitizer according to claims 33-36, wherein the immune checkpoint inhibitor is administered to the individual 20 to 50 hours (optionally 24 to 48 hours) after the laser application.

38. A photosensitizer according to claims 30-37, wherein the cancer or the individual is as defined in claims 1-11.